Age-related Macular Degeneration Market to Progress at a CAGR of 3.4% by 2032 | DelveInsight

13 Jun 2022
www.prnewswire.com
Gene TherapyAntibodyBiosimilarOligonucleotideCell Therapy
The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period.
LAS VEGAS, June 13, 2022 /PRNewswire/ -- DelveInsight's
Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, Age-related macular degeneration emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Key Takeaways from the Age-related Macular Degeneration Market Report
As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately
USD 9.8 billion in 2021.
As per DelveInsight estimation, the Dry AMD market size was approximately
USD 1,377 million, and the Wet AMD market size was approximately
USD 8,463 million, which is further expected to increase by 2032.
As per the estimates, the total Age-related macular degeneration prevalent cases in the 7MM was approximately
51.7 million in 2021.
The Wet Age-related macular degeneration therapies in the pipeline include
The Dry Age-related Macular Degeneration therapies in the pipeline include
The expected launch of therapies and the increasing prevalence will lead to Age-related macular degeneration market growth during the forecast period.
Discover more about therapies set to grab major age-related macular Degeneration market share @
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD)AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular).
The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis.
As per DelveInsight, there were approx
51.7 million Age-related macular degeneration prevalent cases in the 7MM in 2021.
Among the total diagnosed cases of Age-related macular degeneration, the highest cases were observed for dry Age-related macular degeneration in 2021.
The
Age-related macular degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalent Cases of Age-related Macular Degeneration
Total Diagnosed Prevalent Cases of Age-related Macular Degeneration
Type-specific Diagnosed Prevalent Cases of AMDAMD
Total Age-specific Cases of Wet AMD, and Dry AMD
Total Diagnosed Dry AMDAMD Cases by Stages
Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment
Download the report to understand which factors are driving Age-related macular degeneration epidemiology trends @
Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMDAMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMDAMD treatment, effectively stopping the pathophysiological process of AMDAMD and restoring retinal shape and function.
Anti-VEGF therapies such as
ranibizumab, aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo) are intravitreal injections given for wet AMDAMD treatment. Though existing anti-VEGF therapies have transformed the way wet AMDAMD is treated and greatly improved the lives of many patients, they will face stiff competition from new biosimilars and off-label drugs when their patents expire in the coming years. Furthermore, current anti-VEGF therapies have several unmet needs.
Currently, there is no approved dry AMDAMD treatment, and there is a significant unmet need for a therapy to decrease its progression. Dry AMD's pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets.
Several pharmaceutical companies are currently working on developing novel therapies for dry AMDAMD treatment. The therapies in the dry AMDAMD pipeline include
Pegcetacoplan (Apellis Pharmaceuticals), Zimura (Iveric bio), RO7171009; RG6147 (Genentech), IONIS-FB-LRx (Ionis Pharmaceuticals/ Roche), Luminate (Allegro Ophthalmics), NGM621 (NGM Biopharmaceuticals), Elamipretide (Stealth BioTherapeutics), CPCB-RPE1 (Regenerative Patch Technologies), OpRegen (CellCure Neurosciences/Lineage Cell Therapeutics/ Roche), GT005 (Gyroscope Therapeutics), and others.
These therapies come with different types of mechanisms of action, including C3 inhibitorC3 inhibitor, C5 inhibitor, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitor, HtrA1, ASO Complement Factor B, and others. Two C3 inhibitors, NGM621 (NGM Biopharmaceuticals) and pegcetacoplan (Apellis Pharmaceuticals), and one C5 inhibitor, Zimura (Iveric Bio), are showing promise as prospective treatments to slow the course of geographic atrophy.
To know more about Age-related macular degeneration treatment visit @
Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies
OPT-302: Opthea Limited
PAN-90806: PanOptica, Inc.
Others
Dry Age-related Macular Degeneration Pipeline Therapies and Key Companies
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
CPCB-RPE1: Regenerative Patch Technologies
Luminate (Risuteganib): Allegro Ophthalmics
IONIS-FB-LRx: Ionis Pharmaceuticals
Zimura (Avacincaptad Pegol): Iveric Bio
RPESC-RPE-4W: Luxa Biotechnology
Others
Learn more about the dry AMDAMD treatments in clinical trials @
New Treatment for Dry AMD
The
rising prevalence of wet AMDAMD and the
growing geriatric population are two significant factors driving the growth of the wet AMDAMD market. Moreover,  the wet AMD market dynamics are changing as
extensive research and development have helped understand the histopathology and pathophysiology of wet AMDAMD. Development in the
field of gene therapy and a
robust pipeline are also propelling the wet AMD market growth.
However, some factors restrain the growth of the wet AMD market. Patients do not contact a physician until they have intermediate to severe AMDAMD symptoms, making
timely diagnosis extremely difficult. Moreover, the
high cost of therapy, with gene therapy costing over
USD 400,000, presents a significant barrier to treatment availability. In addition, the
competitive treatment landscape and
emerging biosimilars may also limit the growth of the wet AMDAMD market.
The dry AMD market is still untapped. The enormous and growing patient pool with
no approved or adequate therapies provides companies with attractive prospects; the estimated potential is similar to wet AMDAMD. Moreover, the
dry AMD pipeline includes peptide derivatives, antibodies, antisense oligonucleotides, stem cell treatment, and gene therapy that function on various mechanisms such as C1q, C3, and C5 inhibitors, cell replacements, HtrA Serine Peptidase 1 inhibitor, and others. The launch of these therapies will boost the dry AMDAMD market growth. Furthermore, the
increasing prevalence of dry AMDAMD is also driving the dry AMDAMD market forward.
However,
limited knowledge of pathophysiology, disease severity, and consequences affect the development of efficacious treatment for dry AMDAMD. Moreover,
emerging gene therapies and stem cell therapies for dry AMDAMD may face hurdles in access and reimbursement due to their anticipated high cost and will restrain the growth of the dry AMDAMD market.
Scope of the
Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key
Key
Wet
Key
Dry
Therapeutic Assessment: Age-related Macular Degeneration current marketed and emerging therapies
Market Dynamics:  Age-related Macular Degeneration market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views,
Discover more about Age-related macular degeneration drugs in development @
Table of Contents
Get in touch with our Business executive  @
Healthcare Due Diligence Services
Related Reports
Age-related Macular Degeneration Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Age-related Macular Degeneration epidemiology in the 7MM.
Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Age-related Macular Degeneration companies including
, among others.
Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wet Age-related Macular Degeneration companies including
Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dry Age-related Macular Degeneration companies including
Alkeus Pharmaceuticals, Dobecure, Iveric Bio, among others.
Wet Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wet Age-related Macular Degeneration companies including
Dry Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dry Age-related Macular Degeneration companies including
Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, among others.
Other Trending Reports
Periodontal Disease Market | Open-Angle Glaucoma Market | Obsessive-Compulsive Disorder Market | Nicotine Addiction Market | Nephrosclerosis Market | Muscle Invasive Bladder cancer Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market
Related Healthcare Blogs
Dry AMD Market: Pegcetacoplan vs Zimura
Wet Age-related Macular Degeneration Market Outlook
Eye Disorders Treatment Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.